Abstract from Cancer Diagnostics:
Cancer is the second largest cause of death in developed countries, accounting for nearly 1 in 5 of all deaths. The financial costs of cancer are staggering, affecting both the individual and society in general. The U.S. National Institutes of Health (NIH) estimated the overall annual costs for cancer in 2000 at $180 billion in the U.S. alone, with $60 billion for direct medical costs and the rest in cost of lost productivity.

The scope of this report includes the international markets for cancer diagnostics. This report will concentrate on diagnostic tests for cancer detection, monitoring, staging, and prognosis, but will also cover the emerging area of pharmacogenomics and predictive testing that will soon transform the way cancer therapeutics are utilized. This report will also provide an in depth analysis of reagents and instruments used for tumor marker testing and cell analysis.

This report deals with in vitro diagnostic technology used to detect changes that indicate the emergence or growth of human cancers. The emphasis of the report will be on diagnostic instrumentation and reagents for performing tumor marker tests and those companies actively developing and marketing them.

Key objectives of the report include:

• Types of cancer diagnostics that are currently on the market and the instruments that they run on
• Emerging segments of the cancer diagnostic market and types of
• cancer diagnostics in the developmental pipeline
• Status of development and expected launch date of new tests
• Companies participating in the cancer diagnostics segment
• Types of cancers targeted and their prevalence
• Market predictions for the years 2001-2006
• Trends affecting developers including changing demographics, health systems, payor attitudes, and regulatory requirements
• Relevant strategic alliances

Abstract from Cancer Therapeutics:
Cancer accounts for approximately 22% of all deaths, which makes it the second leading cause of death in the U.S. after heart disease. The quest for effective cancer treatments continues to be one of the highest priorities of pharmaceutical companies. This report, "Cancer Therapeutics: Global Markets and Developments" , provides a comprehensive description of current products and advances worldwide in the cancer therapeutics market. The report includes an analysis of potential product offerings and insight into future markets, including market projections. The report offers a detailed analysis of the following issues:

• the market composition and dynamics
• market size and participants with related market shares
• demographics
• economic issues
• regulatory issues

In addiion, historical market data are provided for each year 1996 through 2001, and forecast data are provided for each year 2002 through 2006. Market shares are provided for each market segment for the 2001 base year. Revenues have been divided into and analyzed worldwide including the U.S, Europe, Japan, and the rest of the world.

Please Note: Theta requires that, for PDF orders, clients sign a confidentiality agreement prior to fulfillment of PDF email delivery.

Related Reports:
Prostate Cancer Drug Discoveries: What the Future Holds
Point of Care Diagnostics 2010 and Beyond: Rapid Testing at a Crossroads
Competitor Analysis: TGF-R Agonists and Antagonists
CDK Inhibitors Patent Landscape 2009
Protein Kinase Therapeutics in Oncology - Where to Commercialize?
Pipeline Insight: Colorectal Cancer - Growing trend towards personalized medicine
Stakeholder Insight: Acute Leukemias - Reaching the limits of cytotoxic chemotherapy
Top 20 Cancer Therapy Brands Forecast
2009 Worldwide Diagnostics Market Research Bundle
Innovations in Oncology Diagnostics: Technological advances, growth opportunities and future market outlook